Provided are a sequencing library and applications thereof. The provided sequencing library includes a first nucleic acid molecule and a second nucleic acid molecule. The first nucleic acid molecule carries a cell index sequence and a droplet index sequence. The second nucleic acid molecule carries an insert fragment and a cell index sequence.

Provided are a sequencing library and applications thereof. The provided sequencing library includes a first nucleic acid molecule and a second nucleic acid molecule. The first nucleic acid molecule carries a cell index sequence and a droplet index sequence. The second nucleic acid molecule carries an insert fragment and a cell index sequence.

The invention concerns gene signatures obtained from microvesicles and a method of applying these gene signatures in helping to determine a biological condition. The determination of a biological condition may aid, for example, the diagnosis, prognosis, and therapy treatment selection for disease in a subject.

The invention concerns gene signatures obtained from microvesicles and a method of applying these gene signatures in helping to determine a biological condition. The determination of a biological condition may aid, for example, the diagnosis, prognosis, and therapy treatment selection for disease in a subject.

The invention relates to an in vitro method for isolating nucleic acids associated to or contained inside extracellular vesicles (EVs) from a sample based on the formation of a DMB-EVs precipitate and the isolation of the nucleic acids present in the precipitate. The invention also relates to the use of the method of the invention for diagnosing or for determining the susceptibility of a subject to a disease, for determining the prognosis or for monitoring the progression of a disease, for monitoring the effect of a therapy, for identifying compounds suitable for the treatment of a disease, or for designing a personalized therapy or selecting a patient susceptible to being treated with a therapy for the prevention and/or treatment of a disease. In addition, the invention also relates to a kit comprising dimethylmethylene blue (DMB) and a reagent capable of isolating nucleic acids from EVs, and to its use.

The invention relates to an in vitro method for isolating nucleic acids associated to or contained inside extracellular vesicles (EVs) from a sample based on the formation of a DMB-EVs precipitate and the isolation of the nucleic acids present in the precipitate. The invention also relates to the use of the method of the invention for diagnosing or for determining the susceptibility of a subject to a disease, for determining the prognosis or for monitoring the progression of a disease, for monitoring the effect of a therapy, for identifying compounds suitable for the treatment of a disease, or for designing a personalized therapy or selecting a patient susceptible to being treated with a therapy for the prevention and/or treatment of a disease. In addition, the invention also relates to a kit comprising dimethylmethylene blue (DMB) and a reagent capable of isolating nucleic acids from EVs, and to its use.

The invention relates to compositions and methods for isolating extracellular vesicles (EVs) from a biological fluid sample. The compositions and methods of the invention are based on the combination of a polycation with an extracellular matrix forming polymer. Extracellular vesicles (EVs) are isolated from biological fluids such as blood, serum, plasma, saliva, urine or cerebrospinal fluid, or from the conditioned medium of a cell culture, such as an adult stem cell culture. The use of the isolation methods and compositions of the invention results in a higher EVs recovery, enrichment in exosomes, simplicity, cost-effectiveness, and in the isolation of EVs that retain their biological activities in vitro.

The invention relates to compositions and methods for isolating extracellular vesicles (EVs) from a biological fluid sample. The compositions and methods of the invention are based on the combination of a polycation with an extracellular matrix forming polymer. Extracellular vesicles (EVs) are isolated from biological fluids such as blood, serum, plasma, saliva, urine or cerebrospinal fluid, or from the conditioned medium of a cell culture, such as an adult stem cell culture. The use of the isolation methods and compositions of the invention results in a higher EVs recovery, enrichment in exosomes, simplicity, cost-effectiveness, and in the isolation of EVs that retain their biological activities in vitro.

Disclosed is a method for concentrating extracellular vesicles, comprising preparing a mixture comprising a first fraction and a second fraction by mixing a liquid sample comprising extracellular vesicles, a polysaccharide, and a polyether having an average molecular weight of 20,000 or less, wherein the first fraction comprises a higher concentration of extracellular vesicles than the second fraction, and the first fraction comprises a higher concentration of extracellular vesicles than the liquid sample.

A method for seeding and amplifying target nucleic acids derived from a sample in a cluster at a site on a surface of a substrate includes retaining at least a portion of the target nucleic acids in an inactive form that cannot seed to provide a relatively low concentration of active form target nucleic acids available for seeding. As the active form target nucleic acids seed on the surface of the substrate, they may be amplified. Because the concentration of active form target nucleic acids is low, the likelihood is low that a second active form target nucleic acid will seed at the same site within the same cluster before the first active form target nucleic acid is sufficiently amplified to dominate. Accordingly, the likelihood that the cluster will pass filters is increased relative to traditional seeding and amplification methods employing a higher concentration of active form target nucleic acids.